Keywords: Biomarkers, Deuterium, preclinical, BRAF mutation, [6,6'-2H]glucose
Motivation: Oncogenic BRAF-V600E mutations are common in gliomas in adults and children. The combination of the BRAF-V600E inhibitor dabrafenib and the MEK1/2 inhibitor trametinib improves patient survival. However, there is considerable variation in the durability of response, underscoring the need for early biomarkers of treatment response.
Goal(s): To determine whether dabrafenib/trametinib induces alterations in glucose metabolism that can be leveraged for non-invasive imaging.
Approach: Usage of DMI in clinically relevant BRAF-V600E models
Results: We show that DMI-detectable lactate production from [6,6’-2H]-glucose provides an early readout of response to therapy that precedes volumetric alterations and predicts extended survival in vivo.
Impact: Our studies mechanistically link BRAF/MEK inhibition with downregulation of glycolysis and identify [6,6’-2H]-glucose as a novel contrast agent for imaging early response to therapy. Clinical translation of our studies will enable precision imaging of response to therapy for BRAF-mutant gliomas.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords